KEYMED BIO-B(02162) released its annual performance with a net loss of 523 million yuan for shareholders, a year-on-year increase of 1.44%.
Connoa-B (02162) has announced its annual performance for the year ending December 31, 2025. The group achieved a revenue of 716 million RMB during the period, up by 67% year-on-year; the net loss attributable to owners of the parent company was 523 million RMB, an increase of 1.44% compared to the previous year; the basic loss per share was 1.91 RMB.
KEYMED BIO-B (02162) released its annual performance for the year ending December 31, 2025. The group's revenue for the period was 716 million RMB, an increase of 67% compared to the previous year. The attributable loss to the owners of the parent company was 523 million RMB, an increase of 1.44% compared to the previous year. The basic loss per share was 1.91 RMB.
Related Articles
CLOUDR(09955) released its annual performance, with revenue of 1.623 billion yuan and a gross profit of 775 million yuan.
FIN STREET PPT (01502) published annual performance, with a net profit attributable to shareholders of 107 million yuan, a decrease of 7.5% year-on-year.
On March 26, DL Holdings GP (01709) spent HK$2.4103 million to buy back 1.8 million shares.
CLOUDR(09955) released its annual performance, with revenue of 1.623 billion yuan and a gross profit of 775 million yuan.
FIN STREET PPT (01502) published annual performance, with a net profit attributable to shareholders of 107 million yuan, a decrease of 7.5% year-on-year.
On March 26, DL Holdings GP (01709) spent HK$2.4103 million to buy back 1.8 million shares.
RECOMMEND
Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026
Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026
Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026
